In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

相关研究结果发表在Cell杂志上 ... 可分析>104个T细胞-靶细胞互作事件）与François教授团队的多尺度数学模型，首次揭示T细胞受体（TCR）的双向 ...

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find ...

An international research group led by scientists from the National Center for Tumor Diseases (NCT/UCC) in Dresden has now succeeded for the first time in a phase 1 clinical trial in testing a novel ...

"Super Immune Cells" the Latest Weapon in Battle Against Solid Tumors For more than a decade, cancer has been Judith ...

IMA203 is an autologous, engineered T-cell receptor T-cell therapy (TCR T) that targets PRAME, an intracellular protein displayed as a peptide antigen on the surface of multiple solid tumors via ...

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours Oslo, Norway, 22 April 2025 – ...

Bruker Corporation today announced the launch of the Beacon Discovery ™ Optofluidic System at the upcoming American ...

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, ...